Recent studies have demonstrated neutrophil over-expression of the PRV-1 gene in polycythemia vera (PV) but not in secondary or spurious polycythemia (SP). In order to validate as well as expand upon this novel observation, we conducted a prospective study of 88 subjects; 30 with PV, 22 with SP, 14 with essential thrombocythemia (ET), 12 with myelofibrosis with myeloid metaplasia (MMM), and 10 controls. In order to minimize inter-study methodological differences, we used published real-time PCR-based assay. The proportion of patients with increased neutrophil PRV-1 expression was 83% in PV, 21% in ET, 42% in MMM, 18% in SP, and 0% in controls. All 5 MMM patients with PRV-1 upregulation had an antecedent history of PV. We conclude that neutrophil PRV-1 up-regulation is a characteristic feature of PV that may not be affected by fibrotic transformation. However, quantifying neutrophil PRV-1 mRNA, while complementary to other tests, is not self-sufficient for the diagnosis of PV.
Introduction
Although clinical presentation, serum erythropoietin (Epo) level, and bone marrow histology provide adequate information for the diagnosis of PV in the majority of cases, the possibility of either SP or ET is sometimes entertained and needs to be clarified. In this regard, the traditional PV study group "diagnostic criteria" 1 lack both accuracy and practicality and are being replaced by a "diagnostic algorithm" 2 that utilizes, when necessary, specialized tests including an assay for endogenous erythroid colony (EEC) formation, 3 megakaryocyte/platelet Mpl expression, 4,5 and the more recently described neutrophil PRV-1 expression. 6 Although none of these biological markers are specific to PV, they have certainly provided an additional level of comfort in establishing a working diagnosis.
Quantitative neutrophil PRV-1 measurement has been evaluated in healthy controls as well as patients with PV, SP, ET, and de novo MMM. [7] [8] [9] In the most recent of such studies, the diagnostic accuracy of a quantitative, neutrophil PRV-1 assay was reported to be 100% in distinguishing PV from SP. 7 In the particular study, all 71 patients (100%) with PV but none of 11 patients with SP displayed neutrophil PRV-1 over-expression. In contrast, two previous reports that used a similar quantitative assay found neutrophil PRV-1 mRNA not to be elevated in 4 of 13 8 and 2 of 23 9 patients with PV, respectively. In regards to ET, while one study found PRV-1 upregulation in only 2 of 12 patients (17%), 8 a second study reported a corresponding rate of 67% (10 of 15 patients). 9 In the current study, we sought to independently verify the performance of the quantitative PRV-1 assay in distinguishing PV from SP as well as examine neutrophil PRV-1 expression patterns in ET and MMM (both de novo and post-polycythemic).
Methods
This is a prospective, IRB-approved, single institutional study involving 88 subjects; 30 with In order to minimize inter-study methodological differences, the current study used the original test protocol that was kindly provided by Dr. Heike L. Pahl. 7 Thirty ml of blood, in EDTA, was obtained from each patient during a clinically indicated phlebotomy. All samples were processed within 6 hours at room temperature. Neutrophils were isolated through double density gradient centrifugation using Ficoll-Paque (Sigma, St. Louis, MO). Total RNA was extracted via Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA). Samples were analyzed for both integrity and quantity using the Agilent 2100 bioanalyzer (Agilent Technologies, Inc., Carmel, IN). Reverse transcription and PCR were performed in the single buffer system Taqman One
Step RT-PCR (Applied Biosystems, #4309169). PRV-1 transcripts were amplified by using primers created from the human PRV-1 mRNA GenBank sequence (NM_020406); prv1 forward primer (9 uM; 5'-GCT GTC CAC CAA AAT GAG CAT -3', prv1 reverse primer (0.5 uM; 5'-TTC TCA CGC GCA GAG AAG ATC-3'), and prv1 probe 
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To standardize results, the experiment was run as a relative quantitation assay, incorporating the housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene transcript, which used a JOE reporter dye (Taqman GAPDH Control Reagents, Applied Biosystems, #402869). The amplification of PRV-1 and GAPDH were performed in separate wells of the same 96-well plate using the Taqman ABI Prism 7700 (Applied Biosystems, Foster City, CA). Each sample was analyzed in triplicate for both PRV-1 and GAPDH, with RNA diluted to 50 ng in final suspensions of 50 uL. Data 
Results and Discussion
Median ± SD and range of neutrophil PRV-1 expression values, calculated as the ratio of mean cycle of threshold (C T ) for each triplicate measurement of PRV-1 to GAPDH, are outlined in table 1.
The results are also graphically presented in a figure that accompanies table 1. The current study confirms previous observations regarding the strong association between PV and neutrophil PRV-1 over-expression. The study also demonstrates, for the first time, neutrophil PRV-1 upregulation in PPMM but not in de novo MMM; suggesting a distinct biological difference between PV and MMM. 
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In regards to test sensitivity and specificity, as it pertains to distinguishing PV from SP, our results were different from those of Klippel et al. (100% accuracy rate) 7 but similar to those of both Liu et al. 8 and Kralovics et al. 9 . This clinically relevant discrepancy may not be attributed to methodological differences because assay performance and interpretation were similar among the 4 studies. In the current study, 20 of the 30 patients with PV were receiving active phlebotomy and 17 myelosuppressive drug therapy at the time of study tests. Among the 5 PV patients with normal PRV-1 expression, one was newly diagnosed and manifested all the features of PV (splenomegaly, decreased
Epo level, thrombosis). The other 4 patients were diagnosed within 1 month to 10 years of the test date. Three patients were receiving hydroxyurea therapy for 3, 9, and 10 years, respectively, in addition to phlebotomy in two cases. None of these 5 patients was receiving interferon-therapy, a treatment modality that has been associated with correction of PRV-1 upregulation in PV. This patient has now been followed for 18 months with a normal hemoglobin level. The current study suggests that PRV-1 upregulation may not be either an essential or specific component of PV, in the context of its distinction from both SP and ET. Keeping these limitations in mind, however, a carefully standardized quantitative test for measuring neutrophil mRNA should be a useful addition in the diagnostic armamentarium for PV. 
